Trial reportHaematologica2021
Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study.
Trial report in Haematologica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02280993 (Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy), which is not on this map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse Who Are Eligible for High Dose Treatment Followed by Autologous Peripheral Blood Stem Cell Transplantation (ASCT)
Who cites it
58 citing papers in PubMed, 93 citations in OpenAlex.
- Trial
- Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Trial
- Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma.Annals of oncology : official journal of the European Society for Medical Oncology · 2018Trial
- Relapsed Hodgkin lymphoma: should all patients receive an autologous stem cell transplant? - the PRO.Haematologica · 2026Article
- Role of radiotherapy in refractory/relapsed classical Hodgkin lymphoma in the era of targeted therapies and immunotherapy.Clinical and translational radiation oncology · 2026Review
- Hodgkin lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up.HemaSphere · 2026Article
- Real-world evidence for pembrolizumab gemcitabine vinorelbine and liposomal doxorubicin in classical Hodgkin lymphoma.Blood advances · 2026Article
- Emerging therapeutic strategies for CD30-positive lymphomas.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Expression and prognostic impact of CD73 in classical Hodgkin lymphoma.Annals of hematology · 2026Article
- Classical Hodgkin Lymphoma Today.Mediterranean journal of hematology and infectious diseases · 2026Review
- CD30 as a Target Molecule in the Diagnosis and Therapy of Lymphomas.American journal of hematology · 2026Review
- Encouraging response rates and high mobilization success with brentuximab vedotin plus GDP in adult relapsed/refractory classical Hodgkin lymphoma: A real-world study.Leukemia research reports · 2026Article
- Brentuximab vedotin combined with cisplatin, cytarabine, and dexamethasone treatment in transplant-eligible Korean patients with relapsed or refractory Hodgkin's lymphoma.Blood research · 2025Article
- Outcomes of patients with Hodgkin lymphoma receiving Brentuximab Vedotin (BV) as maintenance therapy after ASCT according to previous exposure to BV. A retrospective analysis of the EBMT Lymphoma Working Party in collaboration with GELTAMO, FIL, LYSA, and Turkish Lymphoma Group.Bone marrow transplantation · 2025Article
- [Treatment challenges and optimal management of classical Hodgkin's lymphoma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Article
- When should we use it? The role of brentuximab vedotin in 2024.Hematology. American Society of Hematology. Education Program · 2024Review
- When to use stem cell transplantation for classical Hodgkin lymphoma.Hematology. American Society of Hematology. Education Program · 2024Review
- Treatment strategies and outcome in relapsed peripheral T-cell lymphoma: results from the Netherlands Cancer Registry.Blood advances · 2024Article
- Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: a propensity score-matched analysis.Blood advances · 2024Article
- Beyond Chemotherapy: Present and Future Perspectives in the Treatment of Lymphoproliferative Disorders.Biomedicines · 2024Review
Corrections and comments
- Commented on by
Authors and funding
20 authors at 12 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Achieving a metabolic complete response (mCR) before high-dose chemotherapy (HDC) and autologous peripheral blood stem-cell transplant (auto-PBSCT) predicts progression free survival (PFS) in relapsed/refractory classical Hodgkin lymphoma (R/R cHL). We added brentuximab vedotin (BV) to DHAP to improve the mCR rate. In a Phase I dose-escalation part in 12 patients, we showed that BV-DHAP is feasible. This Phase II study included 55 R/R cHL patients (23 primary refractory). Treatment consisted of three 21-day cycles of BV 1.8 mg/kg on day 1, and DHAP (dexamethasone 40mg days 1-4, cisplatin 100mg/m2; day 1 and cytarabine 2x2g/m2; day 2). Patients with a metabolic partial response (mPR) or mCR proceeded to HDC/auto-PBSCT. Based on independent central FDG-PET-CT review, 42 of 52 evaluable patients (81% [95% CI: 67-90]) achieved an mCR before HDC/auto-PBSCT, five had an mPR and five had progressive disease (three were not evaluable). After HDC/auto-PBSCT, four patients with an mPR converted to an mCR. The 2-year PFS was 74% [95% CI: 63-86], and the overall survival 95% [95% CI: 90-100]. Toxicity was manageable and mainly consisted of grade 3/4 hematological toxicity, fever, nephrotoxicity, ototoxicity (grade 1/2) and transiently elevated liver enzymes during BV-DHAP. Eighteen patients developed new onset peripheral neuropathy (maximum grade 1/2) and all recovered. In conclusion, BV-DHAP is a very effective salvage regimen in R/R cHL patients, but patients should be monitored closely for toxicity. ClinicalTrials.gov identifier: NCT02280993.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.